Compare BioNano Genomics Inc (BNGO) vs Dolby Laboratories, Inc. (DLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Dolby Laboratories, Inc. — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Dolby Laboratories, Inc. trades at $60.65 (market cap $5.75B). The key difference: Dolby Laboratories, Inc. is far larger — about 420.9× BioNano Genomics Inc's market cap, and Dolby Laboratories, Inc. pays a 2.35% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | DLB | |
|---|---|---|
Market Cap | $13.66M | $5.75B |
Sector | Health | Industrials |
52-Week High | $4.92 | $75.62 |
52-Week Low | $1.06 | $48.51 |
Enterprise Value | $16.26M | $5.12B |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
DLB trades at $60.90, down 1.93% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company has consistently beaten EPS estimates in recent quarters, including Q2 2026 with $0.69 actual versus $0.67 expected. Revenue has been stable around $1.3B annually, with a strong gross profit margin of 87.61% in 2025. Analyst consensus is a Buy with a price target of $87.50, suggesting significant upside. Recent news highlights growth in Dolby Atmos and automotive licensing.
The outlook for DLB is positive, supported by strong fundamentals and analyst optimism, but near-term execution risks and licensing volatility pose challenges. The stock's current valuation metrics, including a P/E of 26.11, appear reasonable given growth prospects. Key risks include revenue fluctuations and competitive pressures in the audio-video sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →
